Regionally advanced nasopharyngeal carcinoma
Conditions
Interventions
experimental group:GP regimen and DDP regimen chemotherapy
Control group:TPF regimen and DDP regimen chemotherapy
Sponsors
The Cancer Hospital of Guizhou Province
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Newly diagnosed patients who did not receive radiotherapy or chemotherapy prior to the start of the clinical trial; 2. The pathological diagnosis was non-keratoic carcinoma of the nasopharyngeal (differentiated or undifferentiated, ie WHO type II or type III); 3. III, IVa patients (AJCC Version 8 staging); 4. Male or non-pregnant women; 5. Aged 18 to 70 years old; 6. Functional status: Karnofsky scale (KPS) > 70; 7. White blood cell (WBC) = 4×10^9/L, hemoglobin (HGB) = 90 g/L, platelet (PLT) = 100×10^9/L (or within the normal range of the laboratory); 8. Liver function: ALT, aspartate transaminase (AST) = 1.5 times the upper limit of normal (ULN); total bilirubin = 1.5 x ULN; 9. Renal function: creatinine clearance = 60 ml/min or serum creatinine = 1.5 x ULN; 10. Patient has signed informed consent.
Exclusion criteria
Exclusion criteria: 1. The histological type is WHO keratinizing squamous cell carcinoma or basal squamous cell carcinoma; 2. Treatment is palliative; 3. History of previous malignant tumors, except for well-treated basal cell carcinoma or squamous cell carcinoma, and cervical carcinoma in situ; 4. Pregnancy or breastfeeding women (women of childbearing age should consider pregnancy test; emphasis on effective contraception during treatment); 5. Have previously received radiation therapy (other than non-melanoma skin cancer with previous lesions outside the target of radiotherapy); 6. Primary and cervical metastatic lesions received chemotherapy or surgery (except for diagnostic treatment); 7. Accompanied by other serious diseases, may bring greater risks or affect the compliance of the trial. Examples include unstable heart disease requiring treatment, kidney disease, chronic hepatitis, uncontrolled diabetes (fasting blood glucose >1.5 x ULN), and mental illness.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Chemotherapy-related toxicities;weight; | — |
Countries
China
Contacts
Public ContactJin Feng
The Cancer Hospital of Guizhou Province
Outcome results
None listed